On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.
A new protocol paper in Sensors describes a chatbot that doses walking like a drug for patients in diabetic foot remission.
A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.
Chronic wounds are biological computers stuck in a boot loop. Sharp debridement is Control-Alt-Delete — the histological reboot that converts a chronic wound back into an acute one. Only then can you run the apps.
A new systematic review finds that roughly one in three adults in remission after a healed diabetic foot ulcer develop a recurrent ulcer within 12 months — a risk comparable to several common cancers. Healing is the beginning of the next chapter, not the end of the story.
FOR IMMEDIATE RELEASE ANTALYA, TURKEY – David G. Armstrong, DPM, MD, PhD, Distinguished Professor of Surgery and Neurological Surgery at the University of Southern California (USC), has been selected to deliver the opening keynote address at the 19th National & 7th International Wound Congress. The event, held at the Titanic Mardan Palace from December 4–7,... Continue Reading →
I Reflections on new work from the International Flow and Toe Research Team (iFORT) One of the most persistent challenges in limb preservation is not the first ulcer — it is the next one. Recurrence remains a defining feature of the disease, with up to 60% of people developing a new ulcer within three years... Continue Reading →
Our friends and colleagues at the Universidad Complutense de Madrid—led by Mateo López-Moral, Marta García-Madrid, Esther García-Morales, Yolanda García-Álvarez, Francisco J. Álvaro-Afonso, and José Luis Lázaro-Martínez—have just published the DIATIME Comparative Efficacy Study, a randomized clinical trial that may help redefine how often we should see patients in remission after a healed diabetic foot ulcerLópez-Moral... Continue Reading →
I An important multicenter study from our colleagues Sen and coworkers and the NIH’s Diabetic Foot Consortium, conducted through the NIDDK Diabetic Foot Consortium, has provided strong evidence that functional closure—not just structural closure—matters when it comes to diabetic foot ulcers (DFUs). Published in Diabetes Care, this prospective noninterventional study followed 418 patients with recently... Continue Reading →
It’s not every day that the professional and the personal intersect in such a deeply life-affirming way. Our latest publication in the International Wound Journal, “Three-Year Recurrence in People With Diabetic Foot Ulcers and Chronic Limb Threatening Ischemia Is Comparable to Cancer,” brought together an extraordinary team of colleagues from UCSF, Baylor College of Medicine, USC,... Continue Reading →
